// App-Quantinova.ai

543 : An Exploratory Analysis of the Potential Disconnect Between Objective Inflammatory Response and Clinical Response Following Certolizumab Pegol Treatment in Patients with Active Axial Spondyloarthritis

Researchers

Presenter

  • Martin Rudwaleit

Principal Investigators

  • Filip Van den bosch

  • Helena Marzo-Ortega

  • Victoria Navarro-Compán

  • Rachel Tham

  • Thomas Kumke

  • Lars Bauer

  • Mindy Kim

  • Lianne Gensler

Medical Centers

  • University of Bielefeld, Klinikum Bielefeld, Bielefeld; Germany Klinikum Bielefeld and Charité Berlin, Germany, and Gent University, Gent, Belgium

  • Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium, VIB Center for Inflammation Research, Ghent, Belgium

  • NIHR, Leeds Teaching Hospitals Trust and LIRMM, University of Leeds, Leeds, United Kingdom

  • Department of Hematology, La Paz University Hospital‐IdiPaz, Madrid

  • UCB Pharma, Slough, UK, Overland Park, KS

  • UCB Pharma, Monheim am Rhein, Germany

  • UCB Pharma, Smyrna, GA

  • Department of Medicine, Division of Gastroenterology, University of California, San Francisco, San Franciso, California, United States

Locations

  • Belgium

  • United Kingdom

  • Spain

  • United States

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Musculoskeletal

Disease

  • Axial spondyloarthritis

  • Ankylosing spondylitis

  • Spondyloarthritis

Biomarkers

  • C reactive protein

Drug/Treatment

  • Certolizumab pegol

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • III

Study Id's

  • NCT01087762

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved